Adjuvant Treatment for Surgically-Treated Cervical Cancer Patients: A Comprehensive Review

TL;DR

This review examines the best adjuvant treatments for cervical cancer patients after surgery, emphasizing personalized care and the need for more research on intermediate-risk cases.

Contribution

The paper provides a comprehensive review of adjuvant treatment strategies for surgically treated cervical cancer patients, highlighting gaps in current guidelines for intermediate-risk cases.

Findings

Low-risk patients generally do not require adjuvant therapy after adequate surgery.

High-risk patients benefit from chemoradiotherapy due to lymph node metastasis or other risk factors.

Intermediate-risk patients remain a controversial group with insufficient evidence to guide treatment decisions.

Abstract

Cervical cancer remains a concerning global health issue, where optimal therapeutic strategy is tailored to the stage of the disease. This review highlights the complexities of adjuvant treatment for surgically treated cervical cancer patients based on FIGO staging, advocating for individualized treatment to achieve monotherapy and minimize treatment-related morbidity. Early-stage and low-risk patients require no adjuvant therapy following adequate surgery. High-risk patients with lymph node metastasis, parametrial involvement, or positive margins need chemoradiotherapy. However, intermediate-risk patients remain a controversial issue. Low quality data fail to support the superiority of chemoradiotherapy over radiotherapy, while observation following adequate surgery seems an acceptable option. Enhanced preoperative diagnostics including MRI, diagnostic conization, and surgical staging may optimize risk stratification. The identified gaps in the current guidelines underscore the need for further research to optimize adjuvant treatment for various risk categories.

Background/Objectives: Cervical cancer (CC) is the fourth most common gynecologic malignancy, disproportionately affecting women in low- and middle-income countries. Despite the effectiveness of HPV vaccination and screening strategies, CC poses a major global health issue, accounting for approximately 94% of annual deaths. Τhis review aims to summarize the current evidence regarding adjuvant treatment indications for surgically treated cervical cancer patients and identify areas where further research is required. Methods: After a literature search, a comprehensive review of the existing guidelines, clinical trials, and cohort studies related to cervical cancer treatment was conducted, focusing on the role of adjuvant therapy in patients classified as at low, intermediate, and high risk for recurrence, who may require no further treatment. Results: Adjuvant therapy is generally unnecessary for low-risk patients, while high-risk patients with lymph node invasion, parametrial involvement, or large tumor size require chemoradiation (CRT). Ιntermediate-risk patients fall into a grey zone, where the necessity of adjuvant therapy is still debatable. Guidelines emphasize the need for individualization in treatment strategies, since, based on the published studies, careful surgery alone and observation can provide similar outcomes to adjuvant therapy. Conclusions: This review emphasizes that achieving monotherapy remains pivotal to optimize outcomes and minimize overtreatment. Definitive adjuvant treatment is indicated for high-risk cases, and intermediate-risk patients may benefit from careful observation following adequate surgical intervention, pointing out the necessity of well-designed clinical trials.

Figures